Affordable Access

deepdyve-link
Publisher Website

Long-term outcomes using the stentless LivaNova-Sorin Pericarbon Freedom™ valve after aortic valve replacement.

Authors
  • Stefanelli, Guglielmo1
  • Pirro, Fabrizio1
  • Olaru, Alina1
  • Danniballe, Giuseppe1
  • Labia, Clorinda1
  • Weltert, Luca2
  • 1 Department of Cardiac Surgery, Hesperia Hospital, Modena, Italy. , (Italy)
  • 2 Department of Cardiac Surgery, European Hospital, Rome, Italy. , (Italy)
Type
Published Article
Journal
Interactive Cardiovascular and Thoracic Surgery
Publisher
Oxford University Press
Publication Date
Jul 01, 2018
Volume
27
Issue
1
Pages
116–123
Identifiers
DOI: 10.1093/icvts/ivy012
PMID: 29481624
Source
Medline
Language
English
License
Unknown

Abstract

Information on the long-term safety, efficacy and durability of third-generation stentless aortic valves is lacking. In this single-centre, single-surgeon retrospective observational study, between 2003 and 2015, consecutive, non-selected aortic valve replacement (AVR) patients were implanted with the LivaNova-Sorin Pericarbon Freedom™, a third-generation stentless aortic xenograft. Changes in clinical and echocardiographic parameters were examined, as were mortality, structural valve deterioration and reoperation, according to age at 5, 10 and 14 years. The mean logistic EuroSCORE was 8.5% in 22 AVR patients (mean age 68.3 years; range 15-89 years). Many patients [n = 139 (43%)] underwent a concomitant procedure. Before AVR, 68.0% of patients were in New York Heart Association (NYHA) Class I or II, and at discharge, mean gradient was 10.0 ± 4.3 mmHg. Follow-up lasted up to 8.9 ± 2.8 years. At the last follow-up, 95.6% of patients were in New York Heart Association Class I or II, the mean gradient was 8.0 ± 3.5 mmHg (P < 0.001) and reduction in interventricular septum thickness and improvement of ejection fraction were significant (both P < 0.001). Early 30-day in-hospital mortality was 1.6% overall and 0% in the AVR-only population. Overall survival probability was 99.9%, 87.9% and 82.7% at 5, 10 and 14 years. Freedom from structural valve deterioration at 14 years was 67.5%, 88.9% and 68.2% in AVR patients overall, in those aged >70 years and in those aged 60-70 years, respectively. Freedom from reoperation at 14 years was 70.3%, 88.3% and 78.0% in the corresponding groups. Sorin Pericarbon Freedom is a valuable aortic bioprosthesis with favourable haemodynamics, particularly in smaller annuli, and durability similar to that of stented valves, which make Sorin Pericarbon Freedom a useful option in AVR.

Report this publication

Statistics

Seen <100 times